Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Legend Biotech Corp ADR
(NQ:
LEGN
)
57.50
+0.12 (+0.21%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Legend Biotech Corp ADR
< Previous
1
2
3
4
Next >
Legend Biotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
August 20, 2024
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech Reports Second Quarter 2024 Results and Recent Highlights
August 09, 2024
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech Appoints Peter Salovey, Ph.D., to its Board of Directors
August 08, 2024
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech Announces Preliminary Results for the Six-Months Ended June 30, 2024
July 26, 2024
From
Legend Biotech USA Inc.
Via
GlobeNewswire
CPI Data Sparks Rally in Biotech Stocks
July 15, 2024
Following lower-than-expected inflation data on Thursday, The biotech sector broke out above resistance, closing the week up 6%, far outperforming the market.
Via
MarketBeat
Topics
ETFs
Economy
Exposures
Interest Rates
Legend Biotech to Host Investor Conference Call on Second Quarter 2024 Results
July 10, 2024
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech Announces Positive Overall Survival Results of Landmark Phase 3 CARTITUDE-4 Trial in Multiple Myeloma
July 02, 2024
CARVYKTI® demonstrated statistically significant and clinically meaningful improvement in overall survival in second interim analysis
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech Shares Data on the Earliest Use to Date of CARVYKTI® in the Treatment of Multiple Myeloma and Important Subgroup Analyses at ASCO and EHA
June 03, 2024
From
Legend Biotech
Via
Business Wire
Legend Biotech to Participate in the Jefferies Global Healthcare Conference
May 29, 2024
From
Legend Biotech Corporation
Via
Business Wire
Legend Biotech to Highlight Leadership in CAR-T Cell Therapy for Patients with Multiple Myeloma at ASCO and EHA
May 23, 2024
From
Legend Biotech Corporation
Via
Business Wire
Legend Biotech Reports First Quarter 2024 Results and Recent Highlights
May 13, 2024
From
Legend Biotech Corporation
Via
Business Wire
CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma
April 22, 2024
From
Legend Biotech Corporation
Via
Business Wire
Legend Biotech to Host Investor Conference Call on First Quarter 2024 Results
April 11, 2024
From
Legend Biotech Corporation
Via
Business Wire
Legend Biotech’s CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma
April 05, 2024
From
Legend Biotech Corporation
Via
Business Wire
Legend Biotech Announces Publication of Inaugural Environmental, Social and Governance (ESG) Report
March 19, 2024
From
Legend Biotech Corporation
Via
Business Wire
CARVYKTI® (ciltacabtagene autoleucel) Receives Recommendation from the U.S. FDA Oncologic Drugs Advisory Committee for Earlier Treatment of Patients with Relapsed/Refractory Multiple Myeloma
March 15, 2024
From
Legend Biotech Corporation
Via
Business Wire
Legend Biotech Reports Fourth Quarter and Full Year 2023 Results and Recent Highlights
March 11, 2024
From
Legend Biotech Corporation
Via
Business Wire
Legend Biotech Announces Positive CHMP Opinion for CARVYKTI® (ciltacabtagene autoleucel) for the Treatment of Patients with Relapsed and Lenalidomide Refractory Multiple Myeloma in Earlier Lines of Therapy
February 23, 2024
From
Legend Biotech Corporation
Via
Business Wire
Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2023 Results
February 13, 2024
From
Legend Biotech Corporation
Via
Business Wire
Legend Biotech Announces Closing of License Transaction for Certain CAR-T Therapies Targeting DLL3
January 03, 2024
From
Legend Biotech Corporation
Via
Business Wire
Legend Biotech to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024
From
Legend Biotech Corporation
Via
Business Wire
Patient-Reported Outcomes from the CARTITUDE-4 Study Showed Clinically Meaningful Improvements in Health-Related Quality of Life and Reductions in Multiple Myeloma Symptoms Following Treatment with CARVYKTI® (ciltacabtagene autoleucel)
December 11, 2023
From
Legend Biotech Corporation
Via
Business Wire
Legend Biotech Reports Third Quarter 2023 Results and Recent Highlights
November 20, 2023
From
Legend Biotech Corporation
Via
Business Wire
Legend Biotech Announces Exclusive, Global License Agreement for Certain CAR-T Therapies Targeting DLL3
November 13, 2023
From
Legend Biotech Corporation
Via
Business Wire
Legend Biotech to Host Investor Conference Call on Third-Quarter Results
November 07, 2023
From
Legend Biotech Corporation
Via
Business Wire
Legend Biotech to Showcase Leadership in Multiple Myeloma Treatment at the ASH 2023 Annual Meeting
November 02, 2023
From
Legend Biotech Corporation
Via
Business Wire
Legend Biotech Reports Second Quarter 2023 Results and Recent Highlights
August 15, 2023
From
Legend Biotech Corporation
Via
Business Wire
Legend Biotech to Host Investor Conference Call on Second-Quarter Results
August 03, 2023
From
Legend Biotech Corporation
Via
Business Wire
Legend Biotech Announces Submission of Supplemental Application to the U.S. FDA for Expanded Use of CARVYKTI® (ciltacabtagene autoleucel)
June 06, 2023
From
Legend Biotech Corporation
Via
Business Wire
Ciltacabtagene Autoleucel (cilta-cel) Reduced Risk of Disease Progression or Death by 74% vs Standard Regimens for Adult Patients with Relapsed and Refractory Multiple Myeloma in CARTITUDE-4 Study
June 05, 2023
From
Legend Biotech
Via
Business Wire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.